ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 994,09
1,00%
Dow Jones
38 225,66
0,00%
DAX
18 058,48
0,85%
Brent Oil
83,625
-0,01%
Bitcoin
60 990,36
3,17%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Axsome Therapeutics Inc (AXSM)

  7. Axsome Therapeutics Inc (AXSM) Actualités

AXSM Axsome Therapeutics Inc

74,19
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:43:19
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Axsome Therapeutics Inc AXSM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 74,19 13:43:19
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
74,19
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202413:00GLOBEAxsome Therapeutics Recognizes May as Mental Health..
15/4/202413:00GLOBEAxsome Therapeutics Highlights Innovative Neuroscience..
10/4/202413:00GLOBEAxsome Therapeutics to Report First Quarter 2024 Financial..
01/4/202413:00GLOBEAxsome Therapeutics Initiates ENGAGE Phase 3 Trial of..
25/3/202412:00GLOBEAxsome Therapeutics Announces Results of CRESCENDO..
25/3/202411:30GLOBEAxsome Therapeutics Announces AXS-12 Achieves Primary..
19/3/202412:00GLOBEAxsome Therapeutics Initiates PARADIGM Phase 3 Trial of..
05/3/202413:00GLOBEAxsome Therapeutics to Present at the Leerink Partners..
01/3/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202400:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202413:00GLOBEAxsome Therapeutics to Present at the TD Cowen 44th Annual..
23/2/202414:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202413:05EDGAR2Form 8-K - Current report
20/2/202413:00GLOBEAxsome Therapeutics Reports Fourth Quarter and Full Year..
20/2/202411:37IHMARKETNEWSMarket Cautiousness Ahead of Retail Giants’ Earnings; Oil..
14/2/202421:46EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
23/1/202413:00GLOBEAxsome Therapeutics to Report Fourth Quarter and Full Year..
08/1/202413:10EDGAR2Form 8-K - Current report
04/1/202413:11EDGAR2Form 8-K - Current report
04/1/202413:00GLOBEAxsome Therapeutics Provides Preliminary Fourth Quarter and..
11/12/202313:00GLOBEAxsome Therapeutics Presents New Data and Post-Hoc Analyses..
07/12/202322:05EDGAR2Form 8-K - Current report
07/12/202313:00GLOBEAxsome Therapeutics Hosts Solriamfetol Virtual Investor..
22/11/202313:00GLOBEAxsome Therapeutics to Host Solriamfetol Virtual Investor..
21/11/202313:00GLOBEAxsome Therapeutics to Present at the Piper Sandler 35th..
06/11/202322:39EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202313:05EDGAR2Form 8-K - Current report
06/11/202313:00GLOBEAxsome Therapeutics Reports Third Quarter 2023 Financial..
06/11/202312:54IHMARKETNEWSMonday’s Wall Street Highlights: Berkshire Hathaway, Tesla,..
02/11/202312:00GLOBEAxsome Therapeutics and the Global Alzheimer’s Disease..
31/10/202312:00GLOBEAxsome Therapeutics to Present at Upcoming Investor..
24/10/202313:00GLOBEAxsome Therapeutics Presents Results of the ACCORD trial of..
11/10/202323:03EDGAR2Form 8-K - Current report
11/10/202313:00GLOBEAxsome Therapeutics Appoints Dr. Sue Mahony to its Board of..
10/10/202313:00GLOBEAxsome Therapeutics to Report Third Quarter 2023 Financial..
02/10/202313:00GLOBEAxsome Therapeutics Joins the National Alliance on Mental..
21/9/202313:00GLOBEAxsome Therapeutics Joins the Global Narcolepsy Community in..
16/9/202300:32EDGAR2Form 144 - Report of proposed sale of securities
16/9/202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202313:03GLOBEAxsome Therapeutics Highlights Commitment to Innovating..
05/9/202313:00GLOBEAxsome Therapeutics to Present at Three Upcoming Investor..
15/8/202313:45EDGAR2Form 8-K - Current report
07/8/202323:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:02EDGAR2Form 8-K - Current report
07/8/202313:00GLOBEAxsome Therapeutics Reports Second Quarter 2023 Financial..
04/8/202322:49EDGAR2Form 8-K - Current report
12/7/202313:00GLOBEAxsome Therapeutics to Report Second Quarter 2023 Financial..
07/7/202322:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07/7/202314:21EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
AXSM
Axsome Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés